Development and evaluation of a novel gene delivery vehicle composed of adenovirus serotype 35.
The capacity of gene delivery vehicles is considered to be a critical factor determining the success of gene therapy. To date, various types of gene delivery vehicle have been developed. Among them, recombinant adeno-virus (Ad) vectors have potential that has favored their worldwide use in vitro and in vivo. Conventional Ad vectors are composed of subgroup C Ad serotype 5 (Ad5), although it has been clarified that the drawbacks of Ad5 vectors are a high seroprevalence of Ad5 in adults and low transduction efficiencies in cells lacking the primary receptor for Ad5, coxsackievirus and adenovirus receptor. To overcome these problems, we developed a novel Ad vector fully composed of Ad serotype 35 (Ad35). Ad35 vectors show a wide tropism for human cells because Ad35 binds to human CD46, which is ubiquitously expressed on almost all human cells, as a primary receptor. In addition, anti-Ad5 antibodies do not inhibit Ad35 vector-mediated transduction and the seroprevalence of Ad35 in adults is lower than that of Ad5. This paper reviews our studies on the development and evaluation of Ad35 vectors. Ad vectors derived from other Ad serotypes different from Ad5, including Ad35, are expected to be gene delivery vehicles alternative to conventional Ad5 vectors.
Sakurai
Fuminori
F
Laboratory of Gene Transfer and Regulation, National Institute of Biomedical Innovation, 7-6-8 Asagi, Saito, Ibaragi, Osaka 567-0085, Japan. sakurai@nibio.go.jp
D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology; D000818:Animals; D018952:Antigens, CD34 / Q000378:metabolism; D001854:Bone Marrow Cells / Q000378:metabolism; D016503:Drug Delivery Systems; D005822:Genetic Vectors / Q000008:administration & dosage*; D006801:Humans; D014677:Pharmaceutical Vehicles; D014161:Transduction, Genetic
D018952:Antigens, CD34; D014677:Pharmaceutical Vehicles